Ozempic constipation and constipation on other GLP-1 medicines
The short answer
Ozempic constipation is on the injection label: in two trials in adults with type 2 diabetes, 5% of patients on 0.5 mg and 3.1% on 1 mg reported it, against 1.5% on placebo. Seven of the eight GLP-1 labels we track list constipation in their tables, including Wegovy at 24% against 11% on placebo. Trulicity's reports it in text, at 3.9% and 3.7% against 0.7% on placebo.
Key takeaways
- Seven of the eight GLP-1 labels list constipation in their tables, and Trulicity's reports it in its text.
- A higher dose didn't always mean more constipation. In Zepbound's table the rate falls as the dose rises.
- Tell your prescriber if constipation persists.
- Get prompt medical attention if it comes with severe or persistent abdominal pain or with vomiting.
- Ask your pharmacist before adding any product to treat constipation, and don't adjust your dose yourself.
How often it was reported in the label's trials
| Reaction | Placebon=958 | 5 mgn=630 | 10 mgn=948 | 15 mgn=941 |
|---|---|---|---|---|
| Constipation | 5% | 17% | 14% | 11% |
| Reaction | Placebon=235 | 5 mgn=237 | 10 mgn=240 | 15 mgn=241 |
|---|---|---|---|---|
| Constipation | 1% | 6% | 6% | 7% |
| Reaction | Placebon=1261 | Wegovy injection 2.4 mg once weeklyn=2116 |
|---|---|---|
| Constipation | 11% | 24% |
| Reaction | Placebon=303 | Wegovy injection 2.4 mg once weeklyn=304 | Wegovy injection 7.2 mg once weeklyn=1311 |
|---|---|---|---|
| Constipation | 8% | 19% | 20% |
| Reaction | Placebon=67 | Wegovy injection 2.4 mg once weeklyn=133 |
|---|---|---|
| Constipation | 2% | 6% |
| Reaction | Placebon=262 | Ozempic 0.5 mgn=260 | Ozempic 1 mgn=261 |
|---|---|---|---|
| Constipation | 1.5% | 5% | 3.1% |
| Reaction | Placebon=1576 | 5.5 mgn=1051 | 9 mgn=1055 | 17.2 mgn=1049 |
|---|---|---|---|---|
| Constipation | 9% | 20% | 27% | 24% |
| Reaction | Placebon=362 | Semaglutide tablets 7 mgn=356 | Semaglutide tablets 14 mgn=356 |
|---|---|---|---|
| Constipation | 2% | 6% | 5% |
| Reaction | Placebon=1941 | Saxendan=3384 |
|---|---|---|
| Constipation | 8.5% | 19.4% |
| Reaction | Placebon=126 | Saxendan=125 |
|---|---|---|
| Constipation | 2.4% | 4.8% |
Each medicine's figures come from its own trials, which differ in dose, length and who took part. They are not a head-to-head comparison.
If you’re constipated on a GLP-1 medicine, tell your prescriber if it persists, and ask your pharmacist what’s suitable alongside your other medicines. Get prompt medical attention if it comes with severe or persistent abdominal pain or with vomiting.
Constipation gets less attention than nausea, but in several label tables it’s reported nearly as often as diarrhea, and in Foundayo’s it’s the second row. Here’s what each label says.
How often is constipation reported?
Each figure is the share of trial patients who reported constipation, beside the placebo group from the same trials. A placebo group gets an inactive treatment instead of the medicine.
Weight management trials in adults
- Wegovy 2.4 mg injection (three trials, up to 68 weeks): 24%, with 11% on placebo. In the 7.2 mg trials in adults with obesity: 20% on 7.2 mg, 19% on 2.4 mg and 8% on placebo.
- Foundayo (two pooled trials): 20% at 5.5 mg, 27% at 9 mg and 24% at 17.2 mg, with 9% on placebo.
- Zepbound (two pooled trials): 17% at 5 mg, 14% at 10 mg and 11% at 15 mg, with 5% on placebo.
- Saxenda (five trials): 19.4%, with 8.5% on placebo.
Type 2 diabetes trials in adults
- Mounjaro (two pooled trials): 6% at 5 mg, 6% at 10 mg and 7% at 15 mg, with 1% on placebo. The label adds that in its cardiovascular outcomes trial, constipation was reported by 13% of patients on Mounjaro.
- Rybelsus (two trials; the label also covers Ozempic tablets): 6% at 7 mg and 5% at 14 mg, with 2% on placebo.
- Ozempic injection (two trials): 5% at 0.5 mg and 3.1% at 1 mg, with 1.5% on placebo.
- Trulicity: not listed in the label’s table. The label’s text gives 3.9% at 0.75 mg and 3.7% at 1.5 mg, with 0.7% on placebo.
In adolescents aged 12 and older with obesity, the Wegovy label reports 6% on 2.4 mg and 2% on placebo, and the Saxenda label reports 4.8% and 2.4%.
The weight management figures run higher than the diabetes figures, and so do their placebo groups (5% to 11%, against 0.7% to 2%). The trials enrolled different people for different lengths of time. That difference is why we don’t rank one medicine against another on these numbers.
Does the dose make a difference?
The tables don’t point in one direction. Zepbound’s rate is highest in its lowest dose group. Foundayo’s is highest in the middle. Ozempic’s and Rybelsus’s are slightly lower at the higher dose, and Mounjaro’s is flat. In Wegovy’s 7.2 mg trials, the 7.2 mg and 2.4 mg groups were one point apart.
Each column reflects the dose patients were assigned to, and everyone passed through the lower doses first. The label tables don’t say at which dose a reaction began.
What do the labels say about timing?
Less than they say for other stomach reactions. The timing sentences in the Zepbound, Foundayo, Ozempic and Rybelsus labels name nausea, vomiting and diarrhea, not constipation. Wegovy’s is broader: gastrointestinal (stomach and bowel) reactions as a group “were most frequently reported during dosage escalation,” the weeks when the dose is being raised.
So for constipation, one label statement applies. On Wegovy, it belongs to a group of reactions reported most often while the dose was being raised.
Related warnings
Every label carries a warning on severe gastrointestinal adverse reactions (side effects). Wegovy’s reports that severe gastrointestinal reactions of any type occurred in 4.1% of adults on the injection and 0.9% on placebo. Saxenda’s reports 4.8% and 1.4%. The same warnings say the medicines are not recommended in people with severe gastroparesis (a stomach that empties very slowly). All of these medicines slow stomach emptying, which the labels state in their warnings about anesthesia.
Constipation with significant pain deserves separate attention. The labels describe persistent or severe abdominal pain, sometimes radiating to the back, as a sign of acute pancreatitis, an inflammation of the pancreas. They also carry a warning on acute gallbladder disease. Our abdominal pain page covers both.
When to contact your prescriber
Tell your prescriber if constipation persists, and get prompt medical attention if it comes with severe or persistent abdominal pain or with vomiting. Don’t adjust your dose yourself.
A pharmacist can check what’s suitable for constipation alongside your other medicines.
For other reactions, see diarrhea, dyspepsia, the full side effects overview and the Wegovy guide.
Frequently asked questions
Does Ozempic cause constipation?
Yes, constipation is in the Ozempic injection label's table. In two trials in adults with type 2 diabetes, 5% of patients on 0.5 mg and 3.1% on 1 mg reported it, compared with 1.5% on placebo. The label's timing sentence names nausea, vomiting and diarrhea, not constipation, so it doesn't say when constipation tended to occur.
Does Wegovy cause constipation?
Yes, constipation is in the Wegovy label's table. In three trials of the 2.4 mg injection in adults with obesity or overweight, 24% of patients on Wegovy reported it, compared with 11% on placebo. In the later trials of the 7.2 mg dose, the figures were 20% on 7.2 mg, 19% on 2.4 mg and 8% on placebo.
Is constipation more common at higher doses?
Not consistently. In Zepbound's table the rate falls as the dose rises: 17% at 5 mg, 14% at 10 mg and 11% at 15 mg, against 5% on placebo. Ozempic shows 5% at 0.5 mg and 3.1% at 1 mg. Mounjaro shows 6%, 6% and 7% across its three doses. The labels don't explain these patterns, and neither do we.
Does Trulicity cause constipation?
Constipation isn't in the Trulicity label's table of common reactions, which only lists reactions reported by a set minimum share of patients. The label reports it in its text instead: 3.9% of patients on 0.75 mg and 3.7% on 1.5 mg, compared with 0.7% on placebo, in pooled trials in adults with type 2 diabetes.
When should I call my prescriber about constipation?
Contact your prescriber if constipation doesn't resolve. Seek prompt medical attention if it comes with severe or persistent abdominal pain or vomiting. The labels warn that stomach and bowel reactions are sometimes severe, and they describe persistent or severe abdominal pain as a possible sign of pancreatitis. Ask your pharmacist before adding any product to treat it.
Sources (8)
- 1.
- 2.
- 3.
- 4.
- 5.
- 6.
- 7.
- 8.
Related pages
- GLP-1 side effects: what the FDA labels report
- Ozempic diarrhea: what the GLP-1 labels report
- Abdominal pain on Wegovy, Zepbound, Ozempic and other GLP-1 medicines
- Dyspepsia and indigestion on Zepbound, Wegovy, Mounjaro and other GLP-1 medicines
- What is Wegovy? Uses, doses, pill and pen, and cost
- Does Ozempic make you tired? Fatigue in the GLP-1 labels
